Merck: research agreement with Yumanity
(CercleFinance.com) - On Wednesday the US biotech company Yumanity announced that it has signed a research agreement with the giant Merck to develop new treatments for neurodegenerative diseases.
Under the terms of this collaboration, Merck will have the opportunity to acquire exclusive rights to two of Yumanity's investigational molecules that are being studied in the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
In addition to an undisclosed upfront payment, Yumanity could receive milestone payments of up to 500 million dollars, depending on how projects progress.
Merck also announced on Wednesday that it will present a number of clinical results at the International AIDS Conference, which will be held virtually next month.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Under the terms of this collaboration, Merck will have the opportunity to acquire exclusive rights to two of Yumanity's investigational molecules that are being studied in the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
In addition to an undisclosed upfront payment, Yumanity could receive milestone payments of up to 500 million dollars, depending on how projects progress.
Merck also announced on Wednesday that it will present a number of clinical results at the International AIDS Conference, which will be held virtually next month.
Copyright (c) 2020 CercleFinance.com. All rights reserved.